Nutraceuticals World Magazine
December 2023
-
State of the Industry Series (Part 1): FDA Restructuring and FTC Activity
FDA’s ongoing reorganization is among the most critical industry issues today.12.04.23
-
State of the Industry Part 2: Supplement Access, Safety, and CBD
State and federal regulators have taken aim at certain products and ingredients.12.04.23
-
State of the Industry Part 3: Communication, Education, and Trust
How can industry build and maintain trust with consumers and other stakeholders?12.04.23
-
State of the Industry Part 4: Advanced/Advancing Technologies and Research
AI has received so much attention, but other technologies are also impacting the nutraceuticals industry.12.04.23
-
State of the Industry Part 5: Advocating Best Practices
From shifting the healthcare paradigm to climate, experts discuss the need for collaboration and transparency.12.04.23
-
State of the Industry Part 6: Business Trends and Innovation
Executives offer their view of today's industry landscape and expectations for the future.12.04.23
-
Radicle Science Aims to Set New Trajectory for Healthcare with Modern Clinical Trial Model
Virtual ‘proof-as-a-service’ concept designed to increase speed and scale while lowering costs.11.29.23
-
How Can the Nutraceuticals Industry Empower More Women?
We consulted experts about efforts to support women in business, and to develop better health solutions.12.01.23
-
The Naturally Proud Network: Supporting Diversity, Equity, and Inclusion
The nonprofit is building a support system for community members, not only for professional development but also for personal growth.11.30.23
-
EditorialConsiderations for the Nutraceuticals Industry in 2024 and BeyondConsumers continue to invest in nutrition products and non-pharmaceutical health options.12.04.23
-
Health E-InsightsCan Ayana Bio’s Plant Cell Cultivation Technology Overcome the Limits of Conventional Agriculture?CEO Frank Jaksch discusses how the company can produce affordable, nutrient-dense ingredients optimized for high bioactive content.11.27.23
-
ColumnsThe High Cost of Consumer Confusion: An Elderberry Case StudyCareful consideration must be paid to ingredient form, how it was processed, level of bioactives, and whether it has been scientifically substantiated.11.20.23
-
ColumnscbdMD Executive Ronan Kennedy on the Company’s Expanding Product PortfolioInterim CEO and CFO discusses new Delta 9 gummies, CBD market challenges, and future expectations.11.13.23
